Wave Life Sciences Ltd. (WVE)

Market Cap	2.08B
Revenue (ttm)	53.61M
Net Income (ttm)	-142.52M
Shares Out	152.52M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	143,150
Open	13.75
Previous Close	13.67
Day's Range	13.34 - 13.78
52-Week Range	3.50 - 16.74
Beta	-1.21
Analysts	Strong Buy
Price Target	21.30 (+56.5%)
Earnings Date	Nov 12, 2024

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 268
• Stock Exchange: NASDAQ
• Ticker Symbol: WVE
• Website: https://www.wavelifesciences.com

Financial Performance

In 2023, Wave Life Sciences's revenue was $113.31 million, an increase of 3005.10% compared to the previous year's $3.65 million. Losses were -$57.51 million, -64.46% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price forecast is $21.3, which is an increase of 56.50% from the latest price.

Price Target

$21.3

(56.50% upside)

Analyst Consensus: Strong Buy